Boehringer's volasertib improves AML survival in Phase II

Boehringer Ingelheim's polo-like kinase (Plk) inhibitor volasertib improved survival by nearly three months for elderly patients with acute myeloid leukemia (AML) in the Phase II clinical trial that served as justification to start the German company's an ongoing Phase III trial.